Investigating the mutations in the SARS-CoV-2 proteins among European countries

Abstract

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new member of the Coronaviridae family, triggering more than 190 million cases and more than two million deaths in European societies. Emerging the new variants due to mutations in genomic regions is foremost responsible for influencing the infectivity and mortality potential of such a virus. In the current study, we considered mutations among spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of SARS-CoV-2 in the Europe continent by exploring the frequencies of mutations and the timeline of emerging them. For this purpose, Amino-acid sequences (AASs) were gathered from the GISAID database, and Mutation tracking was performed by detecting any difference between samples and a reference sequence; Wuhan-2019. In the next step, we compared the achieved results with worldwide sequences. 8.6%, 63.6%, 24.7%, and 1.7% of S, E, M, and N samples did not demonstrate any mutation among European countries. Also, the regions of 508 to 635 AA, 7 to 14 AA, 66 to 88 AA, and 164 to 205 AA in S, E, M, and N samples contained the most mutations relative to the total AASs in both Europe AASs and worldwide samples. D614G, A222V, S477N, and L18F were the first to fifth frequent mutations in S AASs among European samples, and T9I, I82T, and R203M were the first frequent mutations among E, M, and S AASs of the Europe continent. Investigating the mutations among structural proteins of SARS-CoV-2 can improve the strength of therapeutic and diagnostic strategies to efficient combat the virus and even maybe efficient in predicting new emerging variants of concern.